Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 24503805)

1.

Sunitinib therapy in metastatic papillary thyroid cancer.

Gori S, Foglietta J, Rossi M, Hamzaj A, Stocchi L, Galuppo C, Picece V, Puxeddu E, Furlani L.

Tumori. 2013 Nov-Dec;99(6):285e-7e. doi: 10.1700/1390.15470.

2.

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.

Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI.

Thyroid. 2013 Oct;23(10):1277-83. doi: 10.1089/thy.2013.0057. Epub 2013 Jul 17.

3.

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.

J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.

PMID:
22442268
4.

Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.

Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, Rischin D.

Anticancer Drugs. 2008 Jun;19(5):547-52. doi: 10.1097/CAD.0b013e3282fc6cf7.

PMID:
18418222
5.

Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.

Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH.

Cancer Biol Ther. 2011 Sep 1;12(5):458-65. Epub 2011 Sep 1.

PMID:
21725210
6.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

7.

Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.

Kaldrymides P, Kostoglou-Athanassiou I, Gkountouvas A, Veniou E, Ziras N.

Endocrine. 2010 Feb;37(1):6-10. doi: 10.1007/s12020-009-9290-z. Epub 2010 Jan 6. Review.

PMID:
20963554
8.

Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.

Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP.

J Thorac Oncol. 2011 Jun;6(6):1117-20. doi: 10.1097/JTO.0b013e31821529c3.

PMID:
21512407
9.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

10.

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.

Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE.

Am J Surg Pathol. 2006 Feb;30(2):216-22.

PMID:
16434896
11.

Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.

Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C.

Thyroid. 2007 Nov;17(11):1109-15.

PMID:
17727338
12.

Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.

Vogelzang NJ.

J Clin Oncol. 2013 Feb 20;31(6):670-5. doi: 10.1200/JCO.2012.44.4349. Epub 2013 Jan 22.

13.

Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.

Moses W, Weng J, Khanafshar E, Duh QY, Clark OH, Kebebew E.

J Surg Res. 2010 May 15;160(2):179-83. doi: 10.1016/j.jss.2009.05.031. Epub 2009 Jun 17.

PMID:
19765726
14.

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.

Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S.

Endocr J. 2011;58(5):381-93. Epub 2011 Apr 15.

15.

Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.

Henderson YC, Fredrick MJ, Clayman GL.

Arch Otolaryngol Head Neck Surg. 2007 Aug;133(8):810-5.

PMID:
17709622
16.

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG.

Clin Cancer Res. 2010 Nov 1;16(21):5260-8. doi: 10.1158/1078-0432.CCR-10-0994. Epub 2010 Sep 16.

17.

Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.

Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME.

J Clin Endocrinol Metab. 2015 Jan;100(1):E77-81. doi: 10.1210/jc.2014-2246.

PMID:
25353071
18.

Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW.

World J Surg. 2008 May;32(5):722-8. doi: 10.1007/s00268-007-9431-6.

PMID:
18235983
19.

From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.

Albarel F, Conte-Devolx B, Oliver C.

Ann Endocrinol (Paris). 2012 Jun;73(3):155-64. doi: 10.1016/j.ando.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503804
20.

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

Spigel DR, Greco FA, Rubin MS, Shipley D, Thompson DS, Lubiner ET, Eakle JF, Quinn R, Burris HA, Hainsworth JD.

Lung Cancer. 2012 Aug;77(2):359-64. doi: 10.1016/j.lungcan.2012.03.009. Epub 2012 May 3.

PMID:
22560921
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk